Acute promyelocytic leukemia in patients aged over 60 years: Multicenter experience of 34 consecutive unselected patients

Anticancer Research

Volumn 30, Issue 3, 2010, Pages 967-972

  Ferrara, Felicetto ^a   Finizio, Olimpia ^a   D'Arco, Alfonso ^b   Mastrullo, Lucia ^c   Cantore, Nicola ^d   Musto, Pellegrino ^e  

^a CARDARELLI HOSPITAL   (Italy)

^b Umberto I Hospital   (Italy)

^c San Gennaro Hospital   (Italy)

^d S G MOSCATI HOSPITAL   (Italy)

^e REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

Acute promyelocyte leukemia; Older patients; Patient selection

Indexed keywords

CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; RETINOIC ACID; TIOGUANINE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HUMAN; LEUKOCYTOSIS; LOW DRUG DOSE; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77951060503     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE and Petersdorf SH: Age and acute myeloid leukemia. Blood 107: 3481-3485, 2006.
2. Ferrara F and Pinto A: Acute myeloid leukemia in the elderly: current therapeutic results and perspectives for clinical research. Rev Recent Clin Trials 2: 33-41, 2007.
3. Ferrara F, Palmieri S and Leoni F: Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 66: 181-193, 2008.
4. Dombret H, Raffoux E and Gardin C: Acute myeloid leukemia in the elderly. Semin Oncol 35: 430-438, 2008.
5. Malfuson JV, Etienne A, Turlure P, de Revel T, Thomas X, Contentin N, Terré C, Rigaudeau S, Bordessoule D, Vey N, Gardin C, Dombret H; Acute Leukemia French Association (ALFA): Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Acute Leukemia French Association (ALFA). Haematologica 93: 1806-1813, 2008.
6. Sanz MA, Tallman MS and Lo-Coco F: Practice points, consensus, and controversial issues in the management of patients with newly diagnosed acute promyelocytic leukemia. Oncologist 10: 806-814, 2005.
7. Jurcic JG, Soignet SL and Maslak AP: Diagnosis and treatment of acute promyelocytic leukemia. Curr Oncol Rep 9: 337-344, 2007.
8. Wang ZY and Chen Z: Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: 2505-2515, 2008.
9. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK and Lo-Coco F: Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 113: 1875-1891, 2009.
10. Tsimberidou AM, Kantarjian H, Keating MJ and Estey E: Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? Leuk Lymphoma 47: 2282-2288, 2006.
11. Disperati P, Minden MD, Gupta V, Schimmer AD, Schuh AC, Yee KW, Kamel-Reid S, Chang H, Xu W and Brandwein JM: Acute promyelocytic leukemia in patients aged 70 years and over - a single center experience of unselected patients. Leuk Lymphoma 48: 1654-1658, 2007.
12. Mandelli F, Latagliata R, Avvisati G, Fazi P, Rodeghiero F, Leoni F, Gobbi M, Nobile F, Gallo E, Fanin R, Amadori S, Vignetti M, Fioritoni G, Ferrara F, Peta A, Giustolisi R, Broccia G, Petti MC, Lo-Coco F; Italian GIMEMA Cooperative Group. et al: Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 17: 1085-1090, 2003.
13. Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B, Sanz M, Guerci A, Miguel JS, Dela Serna J, Garo C, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux P; European APL Group: Outcome of acute promyelocytic leukemia treated with all transretinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia 19: 230-233, 2005.
14. Sanz MA, Vellenga E, Rayon C, Díaz-Mediavilla J, Rivas C, Amutio E, Arias J, Debén G, Novo A, Bergua J, de la Serna J, Bueno J, Negri S, Beltrán de Heredia JM and Martín G: All-transretinoic acid and anthracyclines monochemotherapy for the treatment of elderly patients withacute promyelocytic leukemia. Blood 104: 3490-3493, 2004.
15. Vardiman JW, Harris N and Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100: 2292-2302, 2002.
16. Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, Boccuni P, Di Noto R, Pane F, Annunziata M, Schiavone EM, De Simone M, Guglielmi C, Del Vecchio L and Lo Coco F: CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 18: 1295-1300, 2000.
17. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
18. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayón C, Barbui T, Díaz-Mediavilla J, Fioritoni G, González JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM and Mandelli F: Definition of relapse risk and role of nonanthracyctine drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96: 1247-1253, 2006.
19. Tallman MS and Altman JK: Curative strategies in acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program, pp. 391-399, 2008.
20. Mathews V, George B, Lakshmi KM Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A and Chandy M: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107: 2627-2632, 2006.
21. Tallman MS: What is the role of arsenic in newly diagnosed APL? Best Pract Res Clin Haematol 21: 659-666, 2008.
22. Lo-Coco F, Ammatuna E, Montesinos P and Sanz MA: Acute promyelocytic leukemia: recent advances in diagnosis and management. Semin Oncol 35: 401-409, 2008.
23. Quezada G, Kopp L, Estey E and Wells RJ: All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Pediatr Blood Cancer 51: 133-135, 2008.
24. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G and Cortes JE: Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.Cancer 109: 1355-1359, 2007.
25. de la Sema J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, Esteve J, Bergua JM, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B and Sanz MA: Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-transretinoic acid and idarubicin. Blood 111: 3395-3402, 2008.
26. Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, Pogliani EM, Di Bona E, Micalizzi C, Kropp M, Venditti A, Tafuri A and Mandelli F: Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104: 1995-1999, 2004.
27. Takeshita A, Shinjo K, Naito K, Matsui H, Sahara N, Shigeno K, Suzumura T, Horii T, Shirai N, Maekawa M, Yada Y, Teshima H, Takeuchi J, Ohnishi K and Ohno R: Two patients with all-transretinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent. Int J Hematol 82: 445-448, 2005.
28. Finizio O, Pezzullo L, Rocco S, Bene L, De Rosa C, Nunziata GR and Mettivier V: Combination of all-trans-retinoic acid and gemtuzumab ozogamicin in an elderly patient with acute promyelocytic leukemia and severe cardiac failure. Acta Haematol 117: 188-190, 2007.
29. Breccia M, Cimino G, Diverio D, Gentilini F, Mandelli F and Lo Coco F: Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. Haematologica 92: 1273-1274, 2007.